ImmunodeficiencySAIDNCT06248957
SYSTEMS-LEVEL ANALYSES OF IMMUNE DYSREGULATION
An observational study of Immunodeficiency and Autoimmune Diseases, run by Karolinska Institutet at 1 site in Sweden.
Trial summary
The aim of the SAID study is to create a national resource in Sweden to enable comprehensive immunological analyses of an extremely complex and clinically challenging group of individuals with variable forms of immune system dysregulation. Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- Immunodeficiency, Autoimmune Diseases, Autoinflammatory Syndrome
- What is being tested?
- Immunomodulation
- How many people
- 500 participants
- Where
- 1 siteSweden
- Study dates
- 1 Jan 2024to 31 Dec 2031
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Study population: All subjects, children and adults in Sweden and referred to Swedish centers with known or suspected immune dysregulation.
Who may be able to join
- Patients of all ages seeking care or being referred for suspected immune dysregulation or with a known immune-mediated disease and failing to respond to standard therapy
Who cannot join
- Healthy control individuals will be excluded on the basis of having a diagnosis of an immune mediated disorder, immunomodulatory treatment or current infection or cancer.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Genia Kretzschmar, M.D contact
Sweden1 site, 1 recruiting
- Recruiting
Karolinska Institutet
Stockholm, SE171 77
Petter Brodin, MD PhD, +46 8 52481396, petter.brodin@ki.se
Petter Brodin, MD PhD
About this study
The aim of the SAID study is to create a national resource in Sweden to enable comprehensive immunological analyses of an extremely complex and clinically challenging group of individuals with variable forms of immune system dysregulation. We hope to establish a biobank of primarily blood and fecal samples from children and adults, with confirmed or suspected immune dysregulation, as well as age- and sex- matched healthy controls, for comparisons of immune cell/mediator alongside various clinical presentations of these immunological diseases as well as microbiome samples as possible a possible modifier of clinical presentations. The project will also include the establishment of a national database with deep immunological data, treatment and clinical outcomes for these patients, accessible to participating researchers and clinicians.
Read the detailed description
BACKGROUND
Immune dysregulation encompasses multiple different conditions in which the immune system does not function properly and displays inappropriate or inadequate responses, overreactions or under-reactions directed towards external or internal targets. It is a broad term, and its manifestations include several different categories of disease:
Immunodeficiencies: These disorders impair the immune system's ability to defend the body against foreign or abnormal cells that invade or attack it (such as bacteria, viruses, fungi, and cancer cells). As a result, unusual bacterial, viral, or fungal infections or lymphomas or other cancers may develop. Primary immunodeficiencies (PIDs) comprise a group of nearly 500 inherited disorders, often due to single-gene mutations that result in the specific impairments in immune function. Secondary immunodeficiencies (SIDs) involve a weakened immune system caused by external sources e.g. chemical (chemotherapy), infection (HIV) or cancer.
Autoimmune Disorders: In these conditions the production of autoantibodies against self-antigens causes the immune system to attack healthy cells and tissues. Some of the most common examples include type 1 diabetes (T1D), rheumatoid arthritis (RA), multiple sclerosis (MS), systemic lupus erythematosus (SLE).
Autoinflammatory Disorders: Here dysregulation of the innate immune system leads to spontaneous and recurrent inflammatory episodes. In contrast to autoimmune diseases where antibodies against self-antigens play a central role, the defect in autoinflammatory diseases often lies in the first responder, innate, arm of the immune system where the defect triggers inappropriate activation of the normal inflammatory response or disables resolution thereof. Examples include familial Mediterranean fever (FMF) and cryopyrin-associated periodic syndromes.
Severe allergies: Allergic reactions are misdirected reactions of the immune system to substances commonly found in the environment. Allergens elicit a T helper 2 immune response, including the involvement of IgE, mast cells, innate lymphoid cells 2 (ILC2), eosinophils, and basophils. Severe Allergy which does not respond to therapy can also indicate underlying immundysregulation.
Lymphoproliferation: Lymphoproliferation (LP) refers to persistent polyclonal, oligoclonal, or monoclonal proliferation of lymphoid cells in the clinical setting of immune dysregulation. Symptoms are non-specific and mimic those of an infection, inflammation, or neoplasia and are characterized by chronic or recurrent lymphadenopathy, hepatosplenomegaly, extranodal infiltration, and/or peripheral blood lymphocytosis. Immune disorders characterized by LP include autoimmune lymphoproliferative syndrome (ALPS) and X-linked lymphoproliferation (XLP).
Attempting to classify and group disorders of immune dysregulation in this way is of course an over-simplification as exemplified by conditions with both autoimmune and autoinflammatory components, such as psoriasis or IBD. For this reason, it has been proposed that manifestations of immune dysregulation should be considered as a continuum with rare monogenic autoimmune disorders at one end, rare monogenic autoinflammatory disorders at the other end, followed by polygenic autoimmune/autoinflammatory conditions respectively, with mixed pattern diseases in the center. In real life, patients with immune dysregulation also often present with more than one disease manifestation which further complicates diagnosis and treatment.
Finally, another factor that must be considered when trying to understand immune dysregulation, is the influence of the microbiome. Disruptions to the microbiota early in life are known to have lasting health effects, including increased risks of immune- mediated diseases such as allergy. However, less is known about the possibility that inborn errors of immunity may also shape the developing microbiome with ensuing health-related consequences, although the role of the microbiome in immune dysfunction is beginning to be appreciated. For example, impaired immunity may alter the intestinal microbiome causing subsequent increased intestinal permeability, with increased exposure to bacterial DNA and an activation of innate and adaptive immune that ultimately perpetuate or exacerbate any defects in immunity.
THE PROBLEM Certain types of immune dysregulation can be extremely rare and diagnosis and appropriate treatment are complicated issues. Some are caused by specific genetic mutations with on average one new genetic mutation associated with immune dysregulation being discovered every month. However, in over half of patients with e.g. autoinflammatory disorders, no genetic cause can be found. Some disorders also affect multiple branches of the immune system due to a broader inappropriate immune response, where signs and symptoms of autoimmunity, allergy, and/or immunodeficiency can all be present in one condition at the same time. A new approach is therefore essential to facilitate diagnosis and personalized treatment of patients with immune dysregulation which we believe will involve more holistic, systems-level analyses of immune cell composition and functional responses. Furthermore, little is known about the interaction between the immune function and microbiome composition, particularly in relation to immune dysregulation, and understanding this interplay may reveal new therapeutic opportunities and enable prediction of adverse outcomes.
SYSTEMS IMMUNOLOGY The human immune system consists of many specialized cell populations that stimulate each other to respond, but also compete for growth factors and directly suppress each other to prevent immune pathology. In this way the whole system functions as a highly integrated network. Since this network is decentralized without any master regulator, all actions in the system, both productive immune responses to microbes and destructive autoimmune attacks on normal tissues, emerge from the combined actions of the many immune cell populations that make up this network. To understand higher order functions in a system this complex, comprehensive analyses involving all cell populations simultaneously are required. Only then can the consequence of activating one, or a few specific cell populations, in the system as a whole be understood. This realization has led to the pursuit of "Systems Immunology", the application of technologies and theories from the field of Systems Biology to understand immune systems. Technological advances, primarily in mass cytometry for high- dimensional immune cell analysis, and high-throughput serum protein analyses, now allow for such detailed profiling of all components that make up human immune systems. We therefore now have the ability to dissect immune responses into their underlying cell-cell and cell-protein interactions.
SCIENTIFIC HYPOTHESIS
- Systems-level analyses of immune cell composition and functional responses can reveal distinct cellular networks and pathways related to immune dysregulation in patients with systemic inflammation and immune dysregulation of unknown cause, providing new targets for treatment and facilitating diagnosis.
- Inter-individual variation in systemic inflammatory diseases could be explained by differences in microbial colonization. We hypothesize that microbiome compositional differences can explain differences among patients with defects in similar immune system pathways.
- By combining systems-level functional analyses with whole genome sequencing (clinical analyses) we can better understand redundant pathways in human immune systems which modulate phenotypes in patients with systemic inflammatory and immune dysregulation diseases.
- Conditions
- Immunodeficiency, Autoimmune Diseases, Autoinflammatory Syndrome, Allergy, Dysregulated Host Response
- Being tested
- Immunomodulation
- Medical subject headings
- Immunologic Deficiency Syndromes, Autoimmune Diseases, Hypersensitivity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ImmunomodulationCombination product
Variable protocols for combined immunomodulatory therapies currently in use for different forms of immune dysregulation
| Study group | Role | What they receive |
|---|---|---|
| Patients with immune dysregulation | Patients sampled before and during different immunomodulatory therapies due to immune system dysregulation. Receives: Combination Product: Immunomodulation | |
| Healthy subjects | Age-matched healthy individuals sampled longitudinally |
What is being measured
The primary outcome is the main question the study is designed to answer.
control of immune dysregulation
Remission and control of immune dysregulation manifested as reduced inflammation, symptom relieve and halted immunoproliferation for examples
Measured: 1-3 months from start of therapy
Secondary outcomes (1)
Exploratory immunological parameters
Systems-level immunomonitoring for exploration of cell state changes in response to therapy
Measured: 1-3 months from start of therapy
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Feb 2024
- Study start1 Jan 2024
- Primary completion31 Dec 2030 (estimated)
- Study completion31 Dec 2031 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ImmunodeficiencyStudies of the same condition, open and under way.
- More trials run by Karolinska InstitutetThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Karolinska Institutet
- Sponsor type
- University, hospital or other
- Collaborators
- Karolinska University Hospital, Skane University Hospital, Sahlgrenska University Hospital, Uppsala University Hospital, Region Halland, Region Jönköping County
- Responsible party
- Principal investigator, Petter Brodin, Karolinska Institutet
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06248957
- Sponsor's protocol ID
- 2023-06579-01
- Other IDs
- 2023
- Acronym
- SAID
- Status last verified
- Jan 2024
- First submitted
- 31 Jan 2024
- Last updated
- 8 Feb 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Feb 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- SYSTEMS-LEVEL ANALYSES OF IMMUNE DYSREGULATION
- ClinicalTrials.gov ID
- NCT06248957
- Acronym / sponsor ID
- SAID / 2023-06579-01
- Conditions
- Immunodeficiency, Autoimmune Diseases, Autoinflammatory Syndrome, Allergy, Dysregulated Host Response
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 500 participants (estimated)
- Lead sponsor
- Karolinska InstitutetUniversity, hospital or other
- Collaborators
- Karolinska University Hospital, Skane University Hospital, Sahlgrenska University Hospital, Uppsala University Hospital, Region Halland, Region Jönköping County
- Study start
- 1 Jan 2024 (actual)
- Primary completion
- 31 Dec 2030 (estimated)
- Study completion
- 31 Dec 2031 (estimated)
- First posted
- 8 Feb 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of the SAID study is to create a national resource in Sweden to enable comprehensive immunological analyses of an extremely complex and clinically challenging group of individuals with variable forms of immune system dysregulation. We hope to establish a biobank of primarily blood and fecal samples from children and adults, with confirmed or suspected immune dysregulation, as well as age- and sex- matched healthy controls, for comparisons of immune cell/mediator alongside various clinical presentations of these immunological diseases as well as microbiome samples as possible a possible modifier of clinical presentations. The project will also include the establishment of a national database with deep immunological data, treatment and clinical outcomes for these patients, accessible to participating researchers and clinicians.
Detailed description
BACKGROUND
Immune dysregulation encompasses multiple different conditions in which the immune system does not function properly and displays inappropriate or inadequate responses, overreactions or under-reactions directed towards external or internal targets. It is a broad term, and its manifestations include several different categories of disease:
Immunodeficiencies: These disorders impair the immune system's ability to defend the body against foreign or abnormal cells that invade or attack it (such as bacteria, viruses, fungi, and cancer cells). As a result, unusual bacterial, viral, or fungal infections or lymphomas or other cancers may develop. Primary immunodeficiencies (PIDs) comprise a group of nearly 500 inherited disorders, often due to single-gene mutations that result in the specific impairments in immune function. Secondary immunodeficiencies (SIDs) involve a weakened immune system caused by external sources e.g. chemical (chemotherapy), infection (HIV) or cancer.
Autoimmune Disorders: In these conditions the production of autoantibodies against self-antigens causes the immune system to attack healthy cells and tissues. Some of the most common examples include type 1 diabetes (T1D), rheumatoid arthritis (RA), multiple sclerosis (MS), systemic lupus erythematosus (SLE).
Autoinflammatory Disorders: Here dysregulation of the innate immune system leads to spontaneous and recurrent inflammatory episodes. In contrast to autoimmune diseases where antibodies against self-antigens play a central role, the defect in autoinflammatory diseases often lies in the first responder, innate, arm of the immune system where the defect triggers inappropriate activation of the normal inflammatory response or disables resolution thereof. Examples include familial Mediterranean fever (FMF) and cryopyrin-associated periodic syndromes.
Severe allergies: Allergic reactions are misdirected reactions of the immune system to substances commonly found in the environment. Allergens elicit a T helper 2 immune response, including the involvement of IgE, mast cells, innate lymphoid cells 2 (ILC2), eosinophils, and basophils. Severe Allergy which does not respond to therapy can also indicate underlying immundysregulation.
Lymphoproliferation: Lymphoproliferation (LP) refers to persistent polyclonal, oligoclonal, or monoclonal proliferation of lymphoid cells in the clinical setting of immune dysregulation. Symptoms are non-specific and mimic those of an infection, inflammation, or neoplasia and are characterized by chronic or recurrent lymphadenopathy, hepatosplenomegaly, extranodal infiltration, and/or peripheral blood lymphocytosis. Immune disorders characterized by LP include autoimmune lymphoproliferative syndrome (ALPS) and X-linked lymphoproliferation (XLP).
Attempting to classify and group disorders of immune dysregulation in this way is of course an over-simplification as exemplified by conditions with both autoimmune and autoinflammatory components, such as psoriasis or IBD. For this reason, it has been proposed that manifestations of immune dysregulation should be considered as a continuum with rare monogenic autoimmune disorders at one end, rare monogenic autoinflammatory disorders at the other end, followed by polygenic autoimmune/autoinflammatory conditions respectively, with mixed pattern diseases in the center. In real life, patients with immune dysregulation also often present with more than one disease manifestation which further complicates diagnosis and treatment.
Finally, another factor that must be considered when trying to understand immune dysregulation, is the influence of the microbiome. Disruptions to the microbiota early in life are known to have lasting health effects, including increased risks of immune- mediated diseases such as allergy. However, less is known about the possibility that inborn errors of immunity may also shape the developing microbiome with ensuing health-related consequences, although the role of the microbiome in immune dysfunction is beginning to be appreciated. For example, impaired immunity may alter the intestinal microbiome causing subsequent increased intestinal permeability, with increased exposure to bacterial DNA and an activation of innate and adaptive immune that ultimately perpetuate or exacerbate any defects in immunity.
THE PROBLEM Certain types of immune dysregulation can be extremely rare and diagnosis and appropriate treatment are complicated issues. Some are caused by specific genetic mutations with on average one new genetic mutation associated with immune dysregulation being discovered every month. However, in over half of patients with e.g. autoinflammatory disorders, no genetic cause can be found. Some disorders also affect multiple branches of the immune system due to a broader inappropriate immune response, where signs and symptoms of autoimmunity, allergy, and/or immunodeficiency can all be present in one condition at the same time. A new approach is therefore essential to facilitate diagnosis and personalized treatment of patients with immune dysregulation which we believe will involve more holistic, systems-level analyses of immune cell composition and functional responses. Furthermore, little is known about the interaction between the immune function and microbiome composition, particularly in relation to immune dysregulation, and understanding this interplay may reveal new therapeutic opportunities and enable prediction of adverse outcomes.
SYSTEMS IMMUNOLOGY The human immune system consists of many specialized cell populations that stimulate each other to respond, but also compete for growth factors and directly suppress each other to prevent immune pathology. In this way the whole system functions as a highly integrated network. Since this network is decentralized without any master regulator, all actions in the system, both productive immune responses to microbes and destructive autoimmune attacks on normal tissues, emerge from the combined actions of the many immune cell populations that make up this network. To understand higher order functions in a system this complex, comprehensive analyses involving all cell populations simultaneously are required. Only then can the consequence of activating one, or a few specific cell populations, in the system as a whole be understood. This realization has led to the pursuit of "Systems Immunology", the application of technologies and theories from the field of Systems Biology to understand immune systems. Technological advances, primarily in mass cytometry for high- dimensional immune cell analysis, and high-throughput serum protein analyses, now allow for such detailed profiling of all components that make up human immune systems. We therefore now have the ability to dissect immune responses into their underlying cell-cell and cell-protein interactions.
SCIENTIFIC HYPOTHESIS
- Systems-level analyses of immune cell composition and functional responses can reveal distinct cellular networks and pathways related to immune dysregulation in patients with systemic inflammation and immune dysregulation of unknown cause, providing new targets for treatment and facilitating diagnosis.
- Inter-individual variation in systemic inflammatory diseases could be explained by differences in microbial colonization. We hypothesize that microbiome compositional differences can explain differences among patients with defects in similar immune system pathways.
- By combining systems-level functional analyses with whole genome sequencing (clinical analyses) we can better understand redundant pathways in human immune systems which modulate phenotypes in patients with systemic inflammatory and immune dysregulation diseases.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Patients with immune dysregulation | – | Combination Product: ImmunomodulationPatients sampled before and during different immunomodulatory therapies due to immune system dysregulation. |
| Healthy subjects | – | –Age-matched healthy individuals sampled longitudinally |
Who may qualify
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
- Study population
- All subjects, children and adults in Sweden and referred to Swedish centers with known or suspected immune dysregulation.
Key inclusion criteria (1 listed)
- Patients of all ages seeking care or being referred for suspected immune dysregulation or with a known immune-mediated disease and failing to respond to standard therapy
Key exclusion criteria (1 listed)
- Healthy control individuals will be excluded on the basis of having a diagnosis of an immune mediated disorder, immunomodulatory treatment or current infection or cancer.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ImmunomodulationVariable protocols for combined immunomodulatory therapies currently in use for different forms of immune dysregulation | Combination product | Patients with immune dysregulation |
Primary outcome
control of immune dysregulation
Time frame: 1-3 months from start of therapy
Remission and control of immune dysregulation manifested as reduced inflammation, symptom relieve and halted immunoproliferation for examples
1 secondary outcome
Exploratory immunological parameters
Time frame: 1-3 months from start of therapy
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Feb 2024.
- Brodin lab websiteLink provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Immunodeficiency
Active, not recruiting
Evaluating the Effectiveness of a Mobile HIV Prevention App to Increase HIV and Sexually Transmitted Infections (STI) Testing and PrEP Initiation Among Rural Men Who Have Sex With Men
HIV Infections, STI
RecruitingObservational study
Natural History of Bronchiectasis
Bronchiectasis, Cystic Fibrosis
Not yet recruiting
PNF RCT to Decrease Alcohol Use and Increase HIV Prevention
HIV (Human Immunodeficiency Virus), Alcohol Misuse
RecruitingObservational study
Genetic Analysis of Immune Disorders
DOK 8, STAT1
RecruitingPhase 1
Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)
Acute Adult T-Cell Leukemia/Lymphoma, Adult T-Cell Leukemia/Lymphoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Genia Kretzschmar, M.D contact
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Immunodeficiency and Autoimmune Diseases, run by Karolinska Institutet at 1 site in Sweden.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 8 Feb 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Petter Brodin, M.D., Ph.D (08 524 813 96 ext. +46, petter.brodin@ki.se), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
control of immune dysregulation (time frame: 1-3 months from start of therapy). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Feb 2024.